跳至主要内容
临床试验/JPRN-UMIN000032674
JPRN-UMIN000032674已完成2 期

Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation. - prospective trial of ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.

Akita University hosipital0 个研究点目标入组 24 人开始时间: 2018年6月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 relapsed myeloma 2 previous treatment history of ixazomib 3 treatment history of some drugs after auto SCT. 4 not tolerable to lenalidomide, bortezomib, dexamethasone 5 with Grade 2 or higher peripheral neuropathy 6 pregnancy 7 Abnormality of blood test 8 CNS involvement 9 Plasma cell leukemia 10 with severe infection 11 with intestinal pneumoniae 12 with double and more cancer 13 without consent of blood transfusion 14 and other

研究者

发起方
Akita University hosipital

相似试验